Our Mission

Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options. Adverum has a robust pipeline and is leveraging its next generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our focus on the patient is supported by clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development.

Our Leadership Team

Print All
Amber Salzman, Ph.D. President and Chief Executive Officer
Leone Patterson Chief Financial Officer
Athena Countouriotis, M.D. Senior Vice President, Chief Medical Officer
Mehdi Gasmi, Ph.D. Chief Science and Technology Officer
Jennifer Cheng, Ph.D., J.D. Vice President and General Counsel
Paul B. Cleveland Chairman
Eric G. Carter, M.D., Ph.D. Director
Mitchell Finer, Ph.D. Co-Founder
Patrick Machado, J.D. Director
Amber Salzman, Ph.D. President and Chief Executive Officer
Richard N. Spivey, Pharm.D., Ph.D. Director
Thomas F. Woiwode, Ph.D. Director

Contact Us

Adverum Biotechnologies
1035 O’Brien Drive
Menlo Park, CA 94025
Tel: 650-272-6269
Fax: 650-362-1908
General Inquiry: info@adverum.com

  • *Indicates required field